As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...
While there are drugs available, such as Zoloft or the new 14-day drug Zurzuvae, options are still limited. Research into ...
Zacks Investment Research on MSN6d
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...
Sage is focused on the goal of establishing ZURZUVAE as the standard of care for women with postpartum depression (PPD). The current commercialization investment plan includes joint sales force ...
The year-over-year revenue decline was due to a $75 million license and milestone revenue recorded in the year-ago quarter SAGE markets its new depression drug Zurzuvae (zuranolone) in partnership ...
“We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback